Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00910962 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

A Phase 2 study of Acute Coronary Syndrome, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
526
Enrollment target
20
Study locations

NCT00910962 is a Phase 2 study of Acute Coronary Syndrome that has completed, run by GlaxoSmithKline. The registered enrollment target is 526 participants, below the 2,709-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00910962, a Phase 2 study of Acute Coronary Syndrome, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
526 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI. Up to approximately 525 subjects will be randomized to meet the MRI recruitment target (90 subjects in substudy.) All subjects will continue to receive the local standard of care for the duration of the study.

Conditions Studied

Acute Coronary Syndrome

Interventions

  • DRUG Placebo
  • DRUG GW856553

Study Locations (20)

California

  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Mission Viejo

Florida

  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - St. Petersburg

Minnesota

  • GSK Investigational Site - Minneapolis
  • GSK Investigational Site - Rochester

New York

  • GSK Investigational Site - Brooklyn
  • GSK Investigational Site - Stony Brook

North Carolina

  • GSK Investigational Site - Durham
  • GSK Investigational Site - Raleigh

Pennsylvania

  • GSK Investigational Site - Allentown
  • GSK Investigational Site - Camp Hill

Alaska

  • GSK Investigational Site - Anchorage

Arizona

  • GSK Investigational Site - Tucson

Trial Details

FieldValue
Enrollment Target 526 participants
Start Date 2009-10-08
Est. Completion 2012-03-06
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00910962

The ClinicalTrials.gov registry entry for NCT00910962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (81% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00910962 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00910962 about?

NCT00910962 is a clinical study titled "A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation". This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI. Up to approximately 525 subjects will be randomized to meet the MRI recruitment target (90 subjects in substudy.) All subjects will ...

What is the current status of trial NCT00910962?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 526 participants. The study started on 2009-10-08. Estimated completion is 2012-03-06.

What conditions does trial NCT00910962 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT00910962?

The interventions under investigation include: Placebo (DRUG), GW856553 (DRUG).

Who is sponsoring clinical trial NCT00910962?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00910962 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Coronary Syndrome

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.